Tag Archive for: CDMRP

Get information about the $370 million in non-dilutive awards from the 2023 Peer Reviewed Medical Research Program (PRMRP).

Since venture investment in life science companies began to slump in 2021, biopharma companies have tightened their belts notch by notch to squeeze more utility from each cent and extend their runways. In this environment, non-dilutive funding has become ever more important, especially for small and mid-sized companies.

Each $1 of non-dilutive funding from NIH translates into $8.38 of private sector investment in R&D. Companies which win non-dilutive funding from organizations such as BARDA, NIH, NSF, and CDMRP, are more likely to receive major equity investments.

NCI and CDMRP are awarding over $7 BILLION in funding for cancer R&D. To learn more, listen to our free webinar about these opportunities.

Find out about more than $7 Billion In Funding Opportunities for Cancer Research – and our webinar all about them

The Peer Reviewed Cancer Research Program (PRCRP) of the Congressionally Directed Medical Research Programs (CDMRP) has just announced $130 million in funding opportunities for fiscal year 2022.

In fiscal year 2022 the Peer Reviewed Cancer Research Program (PRCRP) of the Congressionally Directed Medical Research Programs (CDMRP) will provide funds for research into cancers…

CDMRP announced research funding opportunities for fiscal year 2022. CDMRP aim to fund high-risk, high-gain, high-impact projects which other funding agencies may overlook and thus to fill research gaps in critical areas. The FreeMind Group hosted a webinar about these new opportunities. Get the recording, slides, and critical forms here.

The Congressionally Directed Medical Research Programs (CDMRP) have announced their research funding opportunities for fiscal year 2022. Here’s an overview of the ALS funding opportunities. Learn more about these awards and others in our upcoming webinar, Wednesday, March 30, 2022, 1 PM (Eastern).